Back to Search
Start Over
Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.
- Source :
-
Genomics [Genomics] 2023 Jul; Vol. 115 (4), pp. 110648. Date of Electronic Publication: 2023 May 20. - Publication Year :
- 2023
-
Abstract
- Programmed death-ligand 1 (PD-L1) has been widely used in immunotherapy evaluation of patients with non-small cell lung cancer (NSCLC). However, the effect is not particularly ideal, and the association between PD-L1 and genetic alterations requires more exploration. Here, we performed targeted next-generation sequencing and PD-L1 immunohistochemistry (IHC) testing for PD-L1 expression on both tumor cells (TCs) and tumor-infiltrating immune cells (ICs) in 1549 patients. Our studies showed that surgical method of resection was positively correlated with IC+, and a low tumor mutation burden (TMB) was negatively correlated with TC+. Furthermore, we found that EGFR was mutually exclusive with both ALK and STK11. In addition, the features between PD-L1 expression status and genomic alterations were characterized. These results suggest that clinical characteristics and molecular phenotypes are associated with PD-L1 expression signatures, which may provide novel insights for improving the efficiency of immune checkpoint inhibitors (ICIs) in immunotherapy.<br />Competing Interests: Declaration of Competing Interest All authors affiliated with 3D Medicines Inc. are current or former employees. No potential conflicts of interest were disclosed by the other authors.<br /> (Copyright © 2023. Published by Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 1089-8646
- Volume :
- 115
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Genomics
- Publication Type :
- Academic Journal
- Accession number :
- 37217086
- Full Text :
- https://doi.org/10.1016/j.ygeno.2023.110648